| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Immunic Inc. | Vidofludimus calcium (IMU-838) - (EMPhaSIS) | Relapsing-remitting multiple sclerosis (RMS) | Phase 3 | Data Released | Oral | Neurology |
| Immunic Inc. | Vidofludimus Calcium (IMU-838) - (CALLIPER) | Progressive Multiple Sclerosis | Phase 2 | Data Released | Oral | Neurology |
| ImmunityBio Inc. | ANKTIVA (nogapendekin alfa inbakicept) - (QUILT-2.023) | 1L Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Data Released | Intravesical | Oncology |
| ImmunityBio Inc. | ANKTIVA | NMIBC Papillary Disease | BLA Filing | Ongoing | Intravenous | Oncology |
| ImmunityBio Inc. | ANKTIVA | NMIBC Papillary Disease | BLA Filing | Ongoing | Intravenous | Oncology |
| ImmunityBio Inc. | Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055) | NSCLC, Various tumors | Phase 2b | Data Released | Intravenous | Oncology |
| ImmunityBio Inc. | ANKTIVA - (ResQ201A-NSCLC) | Non-Small Cell Lung Cancer | BLA Filing | Trial Planned | Intravenous | Oncology |
| ImmunityBio Inc. | IL-15 superagonist N-803 - (Tri-Ad5) | Lynch syndrome | Phase 2b | Intravenous | Genetic Disorder |